-

Ribbon Biolabs Appoints Jodi Barrientos as Chief Business Officer

VIENNA--(BUSINESS WIRE)--Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Jodi Barrientos as Chief Business Officer. With over 17 years of experience in industry-leading life science and diagnostics companies, Jodi Barrientos brings deep knowledge and expertise in commercial strategy, operations, and enterprise development focused on key synthetic biology and genomics markets. In her new role, she will be responsible for accelerating the company’s commercial efforts of synthesizing DNA molecules for clients in biopharma, biotech, and academia.

“With the kick-off of our Early Access program, Ribbon will greatly benefit from Jodi’s extensive network in the US, the world’s biggest synthetic DNA market,” said Harold de Vladar, Ph.D., Chief Executive Officer of Ribbon Biolabs. “As we gradually scale up our commercial activities, we are committed to building strong collaborations with biopharma as well as other industry partners and Jodi will play an integral role in this process.”

“Ribbon’s ability to produce synthetic DNA of unprecedented length and complexity has the potential to shape the way the market thinks about the possibilities of their DNA-based applications,” said Jodi Barrientos, Chief Business Officer of Ribbon Biolabs. “I am thrilled to work with the Ribbon team to bring this innovative technology to the market. I look forward to establishing strong alliances as we enter commercial scale production and expand our global footprint.”

Prior to joining Ribbon Biolabs, Barrientos was Vice President of Commercial Marketing for the Diagnostics Genomics Group at Agilent Technologies, where she leveraged her market knowledge and commercial experience to bring innovative products to the genomics, pathology, and companion diagnostics markets. She led global teams focused on building brand awareness, driving market access, and executing key strategic M&A activities. During her tenure at Agilent, Barrientos also held leadership roles in Commercial Operations and Sales in both clinical and research markets. Before joining Agilent Barrientos served in Global Product Management positions at Qiagen GmbH and Field and Technical Applications at Roche Diagnostics. She holds a Bachelor of Science degree in Molecular Biology and Microbiology from Purdue University.

About Ribbon Biolabs
Ribbon Biolabs is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies. With our automated, enzyme-based InfiniSynth® platform, Ribbon Biolabs can provide DNA molecules without size or sequence limitations, at a high level of accuracy and at unprecedented speed. We are pioneering a highly differentiated approach to create value for our partners and for the next wave of innovation in the biopharmaceutical industry.

© Ribbon Biolabs GmbH | www.ribbonbiolabs.com | office@ribbonbiolabs.com

Contacts

Ribbon Biolabs
PR & Communications
Gabriele Schaller
PR@ribbonbiolabs.com

Ribbon Biolabs


Release Versions

Contacts

Ribbon Biolabs
PR & Communications
Gabriele Schaller
PR@ribbonbiolabs.com

Social Media Profiles
More News From Ribbon Biolabs

Ribbon Biolabs Appoints Roopom Banerjee as Executive Chairman

VIENNA--(BUSINESS WIRE)--Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors. He brings 25 years of strategy, operations, business development, financial advisory, and investment experience in early and late-stage life science companies to Ribbon Biolabs. Mr. Banerjee has held executive, management, and board positions at several US- and EU-based companies, including as CEO of RainDance Technologies, which...

Ribbon Biolabs Announces Presentation and Broad Participation at Upcoming SynBioBeta 2023 Conference

VIENNA--(BUSINESS WIRE)--Ribbon Biolabs, the DNA synthesis company, today announced its participation in the SynBioBeta 2023 conference, held from May 23 to May 25, 2023, in Oakland, CA. The company’s presence at the conference includes a Lightning Talk on the impact of synthetic DNA of sub-genomic lengths in industry and research, as well as a company booth. As the largest synthetic biology industry conference, SynBioBeta brings together biological engineers, innovators, entrepreneurs, and inv...

Ribbon Biolabs Reaches Key Milestone with Automation of InfiniSynthTM Platform for Commercial-scale, Unlimited Length DNA Synthesis

VIENNA--(BUSINESS WIRE)--Ribbon Biolabs, the DNA synthesis company, today announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools...
Back to Newsroom